

diabetes

A JOURNAL OF
THE AMERICAN
DIABETES
ASSOCIATION®

PERSPECTIVES IN DIABETES

Heterogeneity in pancreatic β -cell population	D.G. PIPELEERS	777
--	----------------	-----

ORIGINAL ARTICLES

Antibodies to GAD and tryptic fragments of islet 64K antigen as distinct markers for development of IDDM: studies with identical twins	M.R. CHRISTIE, R.Y.M. TUN, S.S.S. LO, D. CASSIDY, T.J. BROWN, J. HOLLANDS, M. SHATTOCK, G.F. BOTTAZZO, AND R.D.G. LESLIE	782
No independent association between <i>HSP70</i> gene polymorphism and IDDM	A. PUGLIESE, Z.L. AWDEH, A. GALLUZZO, E.J. YUNIS, C.A. ALPER, AND G.S. EISENBARTH	788
Concordant glucose induction of glucokinase, glucose usage, and glucose-stimulated insulin release in pancreatic islets maintained in organ culture	Y. LIANG, H. NAJAFI, R.M. SMITH, E.C. ZIMMERMAN, M.A. MAGNUSON, M. TAL, AND F.M. MATSCHINSKY	792
Human islet glucokinase gene: isolation and sequence analysis of full-length cDNA	L.I. KORANYI, Y. TANIZAWA, C.M. WELLING, D.U. RABIN, AND M.A. PERMUTT	807
Association of 24-h cardiac parasympathetic activity and degree of nephropathy in IDDM patients	H. MØLGAARD, P.D. CHRISTENSEN, K.E. SØRENSEN, C.K. CHRISTENSEN, AND C.E. MOGENSEN	812
Differential expression of retinal insulin receptors in STZ-induced diabetic rats	C. ZETTERSTROM, A. BENJAMIN, AND S.A. ROSENZWEIG	818
Visceral obesity in men: associations with glucose tolerance, plasma insulin, and lipoprotein levels	M.-C. POULIOT, J.-P. DESPRÉS, A. NADEAU, S. MOORJANI, D. PRUD'HOMME, P.J. LAPIEN, A. TREMBLAY, AND C. BOUCHARD	826
Nutrition and somatomedin XXIX: molecular regulation of IGFBP-1 in hepatocyte primary culture	B.C. VILLAFUERTE, S. GOLDSTEIN, D.G. ROBERTSON, C.-I. PAO, L.J. MURPHY, AND L.S. PHILLIPS	835
Glucokinase gene is genetic marker for NIDDM in American blacks	K.C. CHIU, M.A. PROVINCE, AND M.A. PERMUTT	843
Familial clustering of insulin sensitivity	B.C. MARTIN, J.H. WARRAM, B. ROSNER, S.S. RICH, J.S. SOELDNER, AND A.S. KROLEWSKI	850
In vivo imaging of insulin receptors in monkeys using ^{18}F -labeled insulin and positron emission tomography	R.C. EASTMAN, R.E. CARSON, K.A. JACOBSON, Y. SHAI, M.A. CHANNING, B.B. DUNN, J.D. BACHER, E. BAAS, E. JONES, K.L. KIRK, M.A. LESNIAK, AND J. ROTH	855
Impaired glucose sensitivity of ATP-sensitive K^+ channels in pancreatic β -cells in streptozotocin-induced NIDDM rats	Y. TSUURA, H. ISHIDA, Y. OKAMOTO, K. TSUJI, T. KUROSE, M. HORIE, H. IMURA, Y. OKADA, AND Y. SEINO	861
Experimental diabetic neuropathy: effect of ganglioside treatment on axonal transport of cytoskeletal proteins	B. FIGLIOMENI, B. BACCI, C. PANOZZO, F. FOGAROLO, C. TRIBAN, AND M.G. FIORI	866
Enhanced glucose tolerance in spontaneously hypertensive rats: pancreatic β -cell hyperfunction with normal insulin sensitivity	T.A. BUCHANAN, J.H. YOUN, V.M. CAMPESE, AND G.F. SIPOS	872
Genetic marker associations with proliferative retinopathy in persons diagnosed with diabetes before 30 yr of age	K.J. CRUICKSHANKS, C.M. VADHEIM, S.E. MOSS, M.-P. ROTH, W.J. RILEY, N.K. MACLAREN, D. LANGFIELD, R.S. SPARKES, R. KLEIN, AND J.I. ROTTER	879

RAPID PUBLICATIONS

Treatment of severely diabetic pancreatectomized dogs using a diffusion-based hybrid pancreas	R.P. LANZA, K.M. BORLAND, P. LODGE, M. CARRETTA, S.J. SULLIVAN, T.E. MULLER, B.A. SOLOMON, T. MAKI, A.P. MONACO, AND W.L. CHICK	886
Stimulation by proinsulin of expression of plasminogen activator inhibitor type-i in endothelial cells	D.J. SCHNEIDER, T.K. NORDT, AND B.E. SOBEL	890



DAEAZ 41(7) 777-895 (1992)
ISSN 0012-1797

*As fast as
blood sugar spills,
Glucotrol
spells...*

Control



Choice brand of endocrinologists¹ **O**nce-daily dosing **N**ear-normal insulin response to meals² **T**olerated well by elderly patients^{*3} **R**eliable safety profile^{*4} **O**nly 30 minutes to onset of action **L**ow cost of therapy⁵

Glucotrol[®]
(glipizide) 5-mg and 10-mg
Scored Tablets 

*Please see brief summary
of GLUCOTROL[®] (glipizide)
prescribing information
on next page.*

When diet alone fails in non-insulin-dependent diabetes mellitus

The reasons to prescribe Glucotrol can pile up fast

Glucotrol
(glipizide) 5-mg and 10-mg
Scored Tablets

References:

1. Medical Marketing Conference. *Antidiabetic Therapy Study V, Tabular Summary*. West Orange, NJ: Market Measures Inc, November 1987-January 1988. 2. Goebel R, Leb G. Effects of glyburide and glipizide on levels of immunoreactive insulin and blood sugar, in *Glipizide: A Worldwide Review*. Princeton, NJ: Excerpta Medica, 1984, pp 9-15. 3. Lipson LG. Diabetes in the elderly: Diagnosis, pathogenesis, and therapy. *Am J Med* 1986;80:10-21. 4. Sachs R, Frank M, Fishman SK. Overview of clinical experience with glipizide, in *Glipizide: A Worldwide Review*. Princeton, NJ: Excerpta Medica, 1984, pp 163-172. 5. *Red Book UPDATE*. Oradell, NJ: Medical Economics Company, August 1988, pp 10, 14, 21.

GLUCOTROL® (glipizide) Tablets

Brief Summary of Prescribing Information

INDICATIONS AND USAGE: GLUCOTROL is indicated as an adjunct to diet for the control of hyperglycemia in patients with non-insulin-dependent diabetes mellitus (NIDDM, type II) after an adequate trial of dietary therapy has proved unsatisfactory.

CONTRAINDICATIONS: GLUCOTROL is contraindicated in patients with known hypersensitivity to the drug or with diabetic ketoacidosis, with or without coma, which should be treated with insulin.

SPECIAL WARNING ON INCREASED RISK OF CARDIOVASCULAR MORTALITY: The administration of oral hypoglycemic drugs has been reported to be associated with increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. The study involved 823 patients who were randomly assigned to one of four treatment groups (*Diabetes*, 19, supp. 2:747-830, 1970).

UGDP reported that patients treated for 5 to 8 years with diet plus a fixed dose of tolbutamide (1.5 grams per day) had a rate of cardiovascular mortality approximately 2-1/2 times that of patients treated with diet alone. A significant increase in total mortality was not observed, but the use of tolbutamide was discontinued based on the increase in cardiovascular mortality, thus limiting the opportunity for the study to show an increase in overall mortality. Despite controversy regarding the interpretation of these results, the findings of the UGDP study provide an adequate basis for this warning. The patient should be informed of the potential risks and advantages of GLUCOTROL and of alternative modes of therapy. Although only one drug in the sulfonylurea class (tolbutamide) was included in this study, it is prudent from a safety standpoint to consider that this warning may also apply to other oral hypoglycemic drugs in this class, in view of their close similarities in mode of action and chemical structure.

PRECAUTIONS: Renal and Hepatic Disease: The metabolism and excretion of GLUCOTROL may be slowed in patients with impaired renal and/or hepatic function. Hypoglycemia may be prolonged in such patients should it occur.

Hypoglycemia: All sulfonylureas are capable of producing severe hypoglycemia. Proper patient selection, dosage, and instructions are important to avoid hypoglycemia. Renal or hepatic insufficiency may increase the risk of hypoglycemic reactions. Elderly, debilitated or malnourished patients and those with adrenal or pituitary insufficiency are particularly susceptible to the hypoglycemic action of glucose-lowering drugs. Hypoglycemia may be difficult to recognize in the elderly or people taking beta-adrenergic blocking drugs. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when alcohol is ingested, or when more than one glucose-lowering drug is used.

Loss of Control of Blood Glucose: A loss of control may occur in diabetic patients exposed to stress such as fever, trauma, infection or surgery. It may then be necessary to discontinue GLUCOTROL and administer insulin.

Laboratory Tests: Blood and urine glucose should be monitored periodically. Measurement of glycosylated hemoglobin may be useful.

Information for Patients: Patients should be informed of the potential risks and advantages of GLUCOTROL, of alternative modes of therapy, as well as the importance of adhering to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose. The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure should also be explained.

Drug Interactions: The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. *In vitro* studies indicate that GLUCOTROL binds differently than tolbutamide and does not interact with salicylate or dicumarol. However, caution must be exercised in extrapolating these findings to a clinical situation. Certain drugs tend to produce hyperglycemia and may lead to loss of control, including the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenyltol, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known.

Carcinogenesis, Mutagenesis, Impairment of Fertility: A 20-month study in rats and an 18-month study in mice at doses up to 75 times the maximum human dose revealed no evidence of drug-related carcinogenicity. Bacterial and *in vivo* mutagenicity

tests were uniformly negative. Studies in rats of both sexes at doses up to 75 times the human dose showed no effects on fertility.

Pregnancy: Pregnancy Category C: GLUCOTROL (glipizide) was found to be mildly fetotoxic in rat reproductive studies at all dose levels (5-50 mg/kg). This fetotoxicity has been similarly noted with other sulfonylureas, such as tolbutamide and tolazamide. The effect is perinatal and believed to be directly related to the pharmacologic (hypoglycemic) action of GLUCOTROL. In studies in rats and rabbits no teratogenic effects were found. There are no adequate and well-controlled studies in pregnant women. GLUCOTROL should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Because recent information suggests that abnormal blood glucose levels during pregnancy are associated with a higher incidence of congenital abnormalities, many experts recommend that insulin be used during pregnancy to maintain blood glucose levels as close to normal as possible.

Nonteratogenic Effects: Prolonged severe hypoglycemia has been reported in neonates born to mothers who were receiving a sulfonylurea drug at the time of delivery. This has been reported more frequently with the use of agents with prolonged half-lives. GLUCOTROL should be discontinued at least one month before the expected delivery date.

Nursing Mothers: Since some sulfonylurea drugs are known to be excreted in human milk, insulin therapy should be considered if nursing is to be continued.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS: In controlled studies, the frequency of serious adverse reactions reported was very low. Of 702 patients, 11.8% reported adverse reactions and in only 1.5% was GLUCOTROL discontinued.

Hypoglycemia: See PRECAUTIONS and OVERDOSAGE sections.

Gastrointestinal: Gastrointestinal disturbances, the most common, were reported with the following approximate incidence: nausea and diarrhea, one in 70; constipation and gastralgia, one in 100. They appear to be dose-related and may disappear on division or reduction of dosage. Cholestatic jaundice may occur rarely with sulfonylureas. GLUCOTROL should be discontinued if this occurs.

Dermatologic: Allergic skin reactions including erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, and eczema have been reported in about one in 70 patients. These may be transient and may disappear despite continued use of GLUCOTROL. If skin reactions persist, the drug should be discontinued. Porphyria cutanea tarda and photosensitivity reactions have been reported with sulfonylureas.

Hematologic: Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, and pancytopenia have been reported with sulfonylureas.

Metabolic: Hepatic porphyria and disulfiram-like alcohol reactions have been reported with sulfonylureas. Clinical experience to date has shown that GLUCOTROL has an extremely low incidence of disulfiram-like reactions.

Endocrine Reactions: Cases of hyponatremia and the syndrome of inappropriate antidiuretic hormone (SIADH) secretion have been reported with this and other sulfonylureas.

Miscellaneous: Dizziness, drowsiness, and headache have each been reported in about one in fifty patients treated with GLUCOTROL. They are usually transient and seldom require discontinuance of therapy.

OVERDOSAGE: Overdosage of sulfonylureas including GLUCOTROL can produce hypoglycemia. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours since hypoglycemia may recur after apparent clinical recovery. Clearance of GLUCOTROL from plasma would be prolonged in persons with liver disease. Because of the extensive protein binding of GLUCOTROL, dialysis is unlikely to be of benefit.

DOSEAGE AND ADMINISTRATION: There is no fixed dosage regimen for the management of diabetes mellitus with GLUCOTROL; in general, it should be given approximately 30 minutes before a meal to achieve the greatest reduction in postprandial hyperglycemia.

Initial Dose: The recommended starting dose is 5 mg before breakfast. Geriatric patients or those with liver disease may be started on 2.5 mg. Dosage adjustments should ordinarily be in increments of 2.5-5 mg, as determined by blood glucose response. At least several days should elapse between titration steps.

Maximum Dose: The maximum recommended total daily dose is 40 mg.

Maintenance: Some patients may be effectively controlled on a once-a-day regimen, while others show better response with divided dosing. Total daily doses above 15 mg should ordinarily be divided.

HOW SUPPLIED: GLUCOTROL is available as white, dye-free, scored, diamond-shaped tablets imprinted as follows: 5 mg tablet—Pizer 411 (NDC 5 mg 0049-4110-66) Bottles of 100; 10 mg tablet—Pizer 412 (NDC 10 mg 0049-4120-66) Bottles of 100.

CAUTION: Federal law prohibits dispensing without prescription.

More detailed professional information available on request.

ROERIG **Pfizer**

A division of Pfizer Pharmaceuticals
New York, New York 10017

CLASSIFIED ADVERTISING

Diabetes Classified Ad rates are:

¼ Page \$370
(for non-ADA members, \$495)

⅛ Page \$180
(for non-ADA members, \$250)

**All advertising must be prepaid
with order.**

**All advertisements will be
typeset uniformly.**

**The closing date for space in
Diabetes is: the first of the month
preceding month of publication;
(December 1st for the January
issue).**

Circulation: 9,000 Paid

**For information on classified
advertising in *Diabetes Care* and
Diabetes Spectrum; and Copy and
Contract Policies, contact:**

**Peggy B. Abbott
American Diabetes Association
1660 Duke Street
Alexandria, VA 22314**

**Telephone: 1-800-232-3472 ext. 312
or 1-703-549-1500
FAX : 1-703-683-2890**

JULY AUTHOR INDEX (Volume 41, Number 7)

- | | |
|-------------------------|-------------------------|
| Alper, C.A., 788 | Monaco, A.P., 886 |
| Awdeh, Z.L., 788 | Moorjani, S., 826 |
| Baas, E., 855 | Moss, S.E., 879 |
| Bacci, B., 866 | Muller, T.E., 886 |
| Bacher, J.D., 855 | Murphy, L.J., 835 |
| Benjamin, A., 818 | Nadeau, André, 826 |
| Borland, K.M., 886 | Najafi, H., 792 |
| Bottazzo, G.F., 782 | Nordt, T.K., 890 |
| Bouchard, C., 826 | Okada, Y., 861 |
| Brown, T.J., 782 | Okamoto, Y., 861 |
| Buchanan, T.A., 872 | Panozzo, C., 866 |
| Campese, V.M., 872 | Pao, C.-I., 835 |
| Carretta, M., 886 | Permutt, M.A., 807, 843 |
| Carson, R.E., 855 | Phillips, L.S., 835 |
| Cassidy, D., 782 | Pipeleers, D.G., 777 |
| Channing, M.A., 855 | Pouliot, M.-C., 826 |
| Chick, W.L., 886 | Province, M.A., 843 |
| Chiu, K.C., 843 | Prud'Homme, D., 826 |
| Christensen, C.K., 812 | Pugliese, A., 788 |
| Christensen, P.D., 812 | Rabin, D.U., 807 |
| Christie, M.R., 782 | Rich, S.S., 850 |
| Cruickshanks, K.J., 879 | Riley, W.J., 879 |
| Després, J.-P., 826 | Robertson, D.G., 835 |
| Dunn, B.B., 855 | Rosenzweig, S.A., 818 |
| Eastman, R.C., 855 | Rosner, B., 850 |
| Eisenbarth, G.S., 788 | Roth, J., 855 |
| Figliomeni, B., 866 | Roth, M.-P., 879 |
| Fiori, M.G., 866 | Rotter, J.I., 879 |
| Fogaro, F., 866 | Schneider, D.J., 890 |
| Galluzzo, A., 788 | Seino, Y., 861 |
| Goldstein, S., 835 | Shai, Y., 855 |
| Hollands, J., 782 | Shattock, M., 782 |
| Horie, M., 861 | Sipos, G.F., 872 |
| Imura, H., 861 | Smith, R.M., 792 |
| Ishida, H., 861 | Sobel, B.E., 890 |
| Jacobson, K.A., 855 | Soeldner, J.S., 850 |
| Jones, E., 855 | Solomon, B.A., 886 |
| Kirk, K.L., 855 | Sørensen, K.E., 812 |
| Klein, R., 879 | Sparkes, R.S., 879 |
| Koranyi, L.I., 807 | Sullivan, S.J., 886 |
| Krolewski, A.S., 850 | Tal, M., 792 |
| Kurose, T., 861 | Tanizawa, Y., 807 |
| Langfield, D., 879 | Tremblay, A., 826 |
| Lanza, R.P., 886 | Triban, C., 866 |
| Leslie, R.D.G., 782 | Tsuji, K., 861 |
| Lesniak, M.A., 855 | Tsuura, Y., 861 |
| Liang, Y., 792 | Tun, R.Y.M., 782 |
| Lo, S.S.S., 782 | Vadheim, C.M., 879 |
| Lodge, P., 886 | Villafuerte, B.C., 835 |
| Lupien, P.J., 826 | Warram, J.H., 850 |
| MacLaren, N.K., 879 | Welling, C.M., 807 |
| Magnuson, M.A., 792 | Youn, J.H., 872 |
| Maki, T., 886 | Yunis, E.J., 788 |
| Martin, B.C., 850 | Zetterström, C., 818 |
| Matschinsky, F.M., 792 | Zimmerman, E.C., 792 |
| Mogensen, C.E., 812 | |
| Mølgaard, H., 812 | |

diabetes

A JOURNAL OF THE AMERICAN DIABETES ASSOCIATION®

Editor

PHILIP E. CRYER, MD

Associate Editors

DAVID D. CHAPLIN, MD, PhD

GEORGE S. EISENBARTH, MD, PhD

MICHAEL L. McDANIEL, PhD

MIKE M. MUECKLER, PhD

M. ALAN PERMUTT, MD

JULIO V. SANTIAGO, MD

JOSEPH R. WILLIAMSON, MD

Editorial Assistant

MARY KHARIBIAN

Editorial Board

GRAEME I. BELL, PhD

SUSAN BONNER-WEIR, PhD

WILLIAM E. CONNOR, MD

BORIS DRAZNIN, MD

MARJORIE DUNLOP, PhD

PETER J. DYCK, MD

ROBERT ECKEL, MD

DAVID E. GOLDSTEIN, MD

BARBARA B. KAHN, MD

AMIRA KLIP, MD

SUZANNE LAYCHOCK, PhD

EDWARD LEITER, PhD

KENNETH L. LUSKEY, MD

MICHAEL J. MACDONALD, MD

MARK MAGNUSON, MD

FRANZ MATSCHINSKY, MD

JOHN P. MORDES, MD

LAWRENCE S. PHILLIPS, MD

ELIZABETH R. SEAQUIST, MD

JAY TABORSKY, MD

HELEN VLASSARA, MD

Publisher

SUSAN H. LAU

Editorial Director

PETER BANKS

Managing Editor

SUSAN WHITE HALE

Assistant Managing Editor

GAIL SHAFFER

Production Editor

STACEY N. WAGES

Assistant Editors

JAMES A. RANSOM

SARAH L. ROBERTS

Publications Assistant

PATRICIA M. WALSH

Advertising Manager

PEGGY B. ABBOTT

Advertising Assistant

AMY E. WOLK

Mission Statements for *Diabetes* and *Diabetes Care*

***Diabetes* publishes original research about the physiology and pathophysiology of diabetes mellitus. Submitted manuscripts can report any aspect of laboratory, animal, or human research. Emphasis is on investigative reports focusing on areas such as the pathogenesis of diabetes and its complications, normal and pathologic pancreatic islet function and intermediary metabolism, pharmacological mechanisms of drug and hormone action, and biochemical and molecular aspects of normal and abnormal biological processes. Studies in the areas of diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus are not published.**

***Diabetes Care* publishes original articles and reviews of human and clinical research intended to increase knowledge, stimulate research, and promote better management of people with diabetes mellitus. Emphasis is on human studies reporting on the pathophysiology and treatment of diabetes and its complications; genetics; epidemiology; psychosocial adaptation; education; and the development, validation, and application of accepted and new therapies. Topics covered are of interest to clinically oriented physicians, researchers, epidemiologists, psychologists, diabetes educators, and other professionals.**

All manuscripts and other editorial correspondence should be sent by first-class mail to Philip E. Cryer, MD, Editor, *Diabetes*, Division of Endocrinology, Diabetes, and Metabolism (Box 8127), Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110.

Diabetes publishes only original material. When submitting a manuscript, authors must state in their transmittal letter that the material has not been published or submitted simultaneously to another journal. Accepted manuscripts incur a charge of \$25 per printed page.

Manuscripts should be prepared in accordance with the requirements specified in the document "Uniform Requirements for Manuscripts Submitted to Biomedical Journals," *Annals of Internal Medicine* 96:766-771, 1982. An "Instructions for Authors" page containing specifications for manuscript preparation appears in the January, April, July, and October issues of each volume.

All material published in *Diabetes* is copyrighted by the American Diabetes Association, Inc. All manuscripts submitted to *Diabetes* must include a transmittal letter stating the following before they will be considered for publication: "In consideration of ADA reviewing my (our) submission, the undersigned author(s) transfers, assigns, or otherwise conveys all copyright ownership to ADA in the event the work is published." Permission to reproduce copyrighted material from *Diabetes* will be granted for limited, noncommercial purposes. Permission requests should be addressed to the Permissions Editor, ADA, 1660 Duke Street, Alexandria, VA 22314, and should be accompanied by a letter of permission from the senior author of the article.

Diabetes (ISSN 0012-1797) is published monthly by the American Diabetes Association, Inc., 1660 Duke Street, Alexandria, Virginia 22314. Professional membership dues include \$50 designated for *Diabetes*. Subscription rates for nonmembers: \$100 for 1 year/\$159 for 2 years in the United States and Canada; \$132 for 1 year/\$233 for 2 years in all other countries. Individual copies: \$10 in the United States and Canada; \$12 in all other countries. Second-class postage paid at Alexandria, Virginia 22314, and at additional mailing offices. POST MASTER: Send change of address to *Diabetes*, American Diabetes Association, P.O. Box 2055, Harlan, IA 51593-0238.

Diabetes is listed in *Science Citation Index*, *MEDLARS*, *Index Medicus*, and *Current Contents (Basic Science and Clinical Medicine)* data bases and *Automatic Subject Citation Alert*. *Diabetes* is available on-line on *BRS Colleague* (for more information, call 800-468-0908) and in machine-readable format from University Microfilms International. *Diabetes* is printed on acid-free paper starting with Vol. 37, 1988.

© 1992 by the American Diabetes Association, Inc.

American Diabetes Association Officers 1992-1993

Chairman of the Board

ROSS V. HICKEY, JR

Chairman of the Board-Elect

MICHAEL A. GREENE

President

F. XAVIER PI-SUNYER, MD

President-Elect

JAMES R. GAVIN III, MD, PhD

Senior Vice President

PATRICIA STENGER, RN, CDE

Vice-Chairman of the Board

DOUGLAS LUND

Vice Presidents

LINDA A. SIMINERIO, RN, MS, CDE

KATHLEEN L. WISHNER, PhD, MD

Secretary

SARA NOLEN

Treasurer

STEPHEN J. SATALINO

Office of the Executive

JOHN H. GRAHAM IV

RICHARD KAHN, PhD

CAROLINE STEVENS

 American
Diabetes
Association.

Acceptance of Manuscripts on Diskette

Diabetes welcomes the submission of manuscripts on computer diskettes beginning with the January 1992 issue. The text stored on diskettes can be used directly for typesetting, improving the efficiency and speed of journal production.

Authors should submit diskettes with the final version of their manuscripts along with the typed revised manuscript. (Do not send diskettes with the initial submission. An exception to this is when a rapid publication is submitted a diskette must accompany the manuscript.) All diskettes must be accompanied by 4 accurate double-spaced paper copies of the manuscript.*

Either 3.5 or 5.25-inch diskettes can be used, and any major word processing program is acceptable. Diskettes may be produced on IBM, IBM-compatible, Apple, or Wang computers.

Diskettes must be labeled with the following information: 1) author's name, 2) article title, and 3) software and hardware used. Detailed instructions for diskette preparation and submission appear in the instructions for authors guidelines in the first issue of every volume.

*Number of paper copies has been changed from that cited in previous issues.

For more than one million patients, our superior accuracy



has become a way of life

For many of your patients, controlling their blood glucose means success in controlling their disease. And knowing that their blood glucose monitor delivers the most accurate values adds to their sense of security. For those patients, Accu-Chek® III is the best recommendation you can make.

Using the same Chemstrip bG® technology that over a million patients and most hospitals rely on, Accu-Chek III delivers the most accurate values.¹ And with its recent system improvements that make testing even easier, 99% of Accu-Chek III users are satisfied.² For you, this may be no surprise—just a great comfort.

**To find out more, call
1-800-858-8072**

1. Based on the published data of competitive monitors.
2. Based on survey of Accu-Chek III Warranty Card respondents.


Accu-Chek® III
BLOOD GLUCOSE MONITOR & CHEMSTRIP bG® TEST STRIPS

Quite simply, the most accurate

**BOEHRINGER
MANNHEIM
CORPORATION**

Boehringer Mannheim Corporation
Patient Care Systems Division
9115 Hague Road, P.O. Box 50100
Indianapolis, IN 46250-0100





More Than 7 Million People Don't Even Know They Have Diabetes.

—*Diabetes: 1991 Vital Statistics*, pg. 1

You'll find hundreds of timely and vital diabetes statistics like this in ADA's latest fact-filled publication.

Almost every imaginable statistic on diabetes has been gathered for you by ADA and published under one brand new title—*Diabetes: 1991 Vital Statistics*.

Designed as a quick reference manual, *Diabetes: 1991 Vital Statistics* is filled with more than 30 easy-to-read charts and graphs that highlight the latest diabetes statistics. Examples include:

- More than 725,000 new cases of diabetes are diagnosed each year.
- Mexican Americans are three times as likely to develop NIDDM as whites.
- The prevalence of NIDDM is 60 percent higher in blacks than in whites.
- Much more!

There's also a convenient bibliography of tables and figures at the back of the book. It's a great

time-saver when you need to make a quick statistical reference.

Diabetes: 1991 Vital Statistics also contains page after page of information to help you diagnose diabetes and treat and prevent complications. Informative topics include:

- How Diabetes is Diagnosed
- Risk Factors for Diabetes
- Diabetes Complications
- Diabetes Treatment and Prevention
- Much more!

Diabetes: 1991 Vital Statistics provides the latest diabetes statistics and important treatment information. It's sure to be a valuable addition to your personal library.


So order your copy of *Diabetes: 1991 Vital Statistics* today. And become the source for the most timely diabetes information available.

Yes!

Please send me _____ copies of *Diabetes: 1991 Vital Statistics* at \$6.25 per copy for members or \$6.95 per copy for nonmembers. I will be sure to add shipping and handling using the chart below.

Publication Total \$ _____
 Virginia Residents Add 4.5% sales tax \$ _____
 Orders outside the U.S., please
 add \$15 for each airmail shipment \$ _____
 Add shipping & handling (use chart) \$ _____
 GRAND TOTAL \$ _____

Shipping & Handling Chart	
Up to \$5.00	add \$1.75
\$5.01-\$10.00	add \$3.00
\$10.01-\$25.00	add \$4.50
\$25.01-\$50.00	add \$5.50
over \$50.00	add 10% of order



Name _____

Address _____

City _____ State _____ Zip _____

Send your check or money order payable to:

American Diabetes Association®
 1970 Chain Bridge Road
 McLean, VA 22109-0592

PJ39301

Allow 6-8 weeks for delivery. Add \$3.00 to shipping & handling for each additional shipping address. Foreign orders must be paid in U.S. funds, drawn on a U.S. bank. Prices subject to change without notice.

Practical Diabetes Information...



...at your fingertips.

Keep one year of DIABETES (12 issues) at hand with one slipcase or binder. Bound in attractive blue leatherette and embossed with gold lettering, each makes a handsome addition to your library. And each comes with gold transfers, allowing you to personalize your volume further. These durable, stylish cases make affordable gifts as well.

SLIPCASES: \$7.95 each, three for \$21.95, six for \$39.95

BINDERS: \$9.95 each, three for \$27.95, six for \$52.95

MAIL TO: Jesse Jones Industries, Dept. DIAB
499 East Erie Avenue, Philadelphia, PA 19134

Please send _____ cases; _____ binders

Enclosed is \$ _____. Add \$1 per item for Postage and Handling.

Outside U.S.A. add \$2.50 per item (U.S. funds only).

Print Name _____

Address _____
(No PO Boxes Please)

City/State/Zip _____

PA residents add 6% sales tax

We also accept American Express, Visa, MasterCard and Discover Club (for minimum orders of \$15.00). CALL TOLL FREE (charge orders only) 1-800-825-6690. 7 days, 24 hours.

NOTE: Satisfaction guaranteed.

Slipcases are also available for DIABETES CARE, DIABETES SPECTRUM and DIABETES FORECAST.

For information write:
American Diabetes Association
1660 Duke Street,
Alexandria, VA 22314
Attn: Circulation Dept



THE GREAT SOUTHWEST

Practice Opportunities

Practice opportunities are now available in the following communities where Humana owns and operates hospitals:

BEAUMONT, TEXAS - A 36-year-old Endocrinologist seeks associate for his 100% Endocrinology practice in a 300,000 service area. He is medical director of the 25-bed Diabetes Unit at our 250-bed hospital.

DALLAS, TEXAS - A busy two-man group in North Dallas now recruiting a third member. Their 100% Endocrinology practice is located on campus of our 555-bed hospital.

LAS VEGAS, NEVADA - Our 688-bed hospital is seeking a Medical Director for its 15-bed Diabetes Unit, which has capacity to expand to 32-beds. It is supported by specialized physicians and nursing staff, clinical research and latest technology. Also, option to associate with an established Endocrinologist.

For more information send CV to Gordon Crawford, Professional Recruitment, Humana Inc., Dept. DI7-2D, P.O. Box 1438, Louisville, KY 40201-1438, or call TOLL FREE 1-800-626-1590, ext. 245.



Physician Placement Services

CLASSIFIED ADVERTISING

Diabetes Classified Ad rates are:

¼ Page \$495 (for members of ADA, \$370)

½ Page \$250 (for members of ADA, \$180)

For information on closing dates; Copy and Contract Policies; and Classified Advertising rates for **Diabetes Care**, contact:




Peggy B. Abbott
American Diabetes Association
1660 Duke Street
Alexandria, VA 22314

Telephone: 1-800-232-3472 ext. 312
or 1-703-549-1500
FAX : 1-703-683-2890

All The Recommendation We Think You Need.

“These manuals contain concepts that are essential to the education of every person who undertakes the care of persons with diabetes mellitus. They are highly recommended for medical students, resident physicians, and nurse clinicians.”

Roger W. Turkington, MD
Book Review, JAMA, May 26, 1989
Vol. 20, p. 3037, Copyright 1989



Color slide programs, designed to follow the *Guides*, are available for group presentations. Presenter's scripts are included.

Authoritative Resources from the American Diabetes Association.

_____ I am an ADA member and want to take advantage of my member discount.
My Membership Number is _____
(See mailing label on *Diabetes Forecast*)

Please send me

- _____ copies, **Physician's Guide to IDDM #PTIPG**
ADA Members: \$17.95; Nonmembers: \$19.95 \$ _____
_____ sets, **IDDM Slide Presentation #PTISS**. ADA
Members: \$81.00; Nonmembers: \$90.00 \$ _____
_____ copies, **Physician's Guide to NIDDM #PTIIPG**.
ADA Members: \$17.95; Nonmembers: \$19.95 \$ _____
_____ sets, **NIDDM Slide Presentation #PTISS**.
ADA Members: \$81.00; Nonmembers: \$90.00 \$ _____

Publications Subtotal \$ _____

VA Residents add 4.5% State Sales Tax \$ _____

Add Shipping & Handling (see chart) \$ _____

TOTAL \$ _____

Name _____

Address _____

City _____

State _____ Zip _____

PJ39302

Shipping & Handling Chart (calculate using publications subtotal)
up to \$5.00 \$1.75 \$25.01-\$50.00 \$5.50
\$5.01-\$10.00 \$3.00 over \$50.00 . 10% of order
\$10.01-\$25.00 \$4.50

To order, send your check or money order payable to the American Diabetes Association, 1970 Chain Bridge Road, McLean, VA 22109-0592. Please allow 6-8 weeks for domestic delivery. Add \$3.00 to shipping & handling for each additional "ship to" address. Add \$15.00 to shipping & handling for air shipped orders outside the U.S. Prices subject to change without notice.


 **American
Diabetes
Association.**

The world's leading diabetes experts just wrote the only therapy manual you'll ever need.

Imagine not having to wade through volume after volume of diabetes therapy textbooks that consume too much of your time. Or having the expertise of more than 50 diabetes professionals at your fingertips in one new publication.

Well, the world's leading diabetes experts just wrote the only therapy manual you'll ever need. And it's easy to use!

Therapy for Diabetes Mellitus and Related Disorders has just been published by the American Diabetes Association and is the authoritative guide to diabetes therapy. It's a "how to" reference manual filled with all the information you need to provide the best care for your patients. Yet each of the 49 chapters average just seven pages, so you'll be able to digest the latest in treatment



- Treating diabetic nerve, eye, and kidney disease
- Controlling blood lipid abnormalities in diabetic patients
- Managing diabetic ketoacidosis and hyperglycemic hyperosmolar coma
- Much, much more!

Therapy for Diabetes Mellitus is also filled with more than 170 charts and tables, making each chapter easier to read and understand. Also, the manual's pocket-sized format will allow you to carry it with you for

and therapy in minutes.

You'll learn about:

- The latest drugs for treating diabetes, including sulfonylureas, metformin, and alpha-glucosidase inhibitors
- Genetic counseling for type I diabetes

quick reference whenever necessary.


So order your copy of *Therapy for Diabetes Mellitus and Related Disorders* today. And put the most comprehensive and easy-to-use therapy manual in your pocket.

Yes!

Please send me _____ copies of *Therapy for Diabetes Mellitus and Related Disorders* at \$22.45 for members or \$24.95 for nonmembers. I will be sure to add shipping and handling using the chart below.

Publication Total \$ _____
 Virginia Residents Add 4.5% sales tax \$ _____
 Orders outside the U.S., please add \$15 for each airmail shipment \$ _____
 Add shipping & handling (use chart) \$ _____
 GRAND TOTAL \$ _____

Shipping & Handling Chart			
Up to \$5.00 add \$1.75	\$25.01-\$50.00 add \$5.50
\$5.01-\$10.00 add \$3.00	over \$50.00 add 10% of order
\$10.01-\$25.00 add \$4.50		




Name _____
 Address _____
 City _____ State _____ Zip _____

Send your check or money order payable to:

American Diabetes Association®
 1970 Chain Bridge Road
 McLean, VA 22109-0592

Allow 6-8 weeks for delivery. Add \$3.00 to shipping & handling for each additional shipping address. Foreign orders must be paid in U.S. funds, drawn on a U.S. bank. Prices subject to change without notice.

PJ49202



Because One Size Doesn't Fit All...

Eli Lilly and Company can suit all your needs with the most complete line of human insulins available.

Featuring Humulin 70/30* and our latest addition to the premixed line, Humulin 50/50† –especially useful in situations in which a greater insulin response is desirable for greater glycemic control.



Humulin®
human insulin
(recombinant DNA origin)

*Tailor-made options in
insulin therapy*

WARNING: Any change of insulin should be made cautiously and only under medical supervision.

*Humulin® 70/30 (70% human insulin isophane suspension, 30% human insulin injection [recombinant DNA origin]).

†Humulin® 50/50 (50% human insulin isophane suspension, 50% human insulin injection [recombinant DNA origin]).



Global Excellence in Diabetes Care
Eli Lilly and Company
Indianapolis, Indiana
46285